Literature DB >> 20831479

Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET.

Morten Busk1, Ole Lajord Munk, Steen Jakobsen, Tobias Wang, Marianne Skals, Torben Steiniche, Michael Robert Horsman, Jens Overgaard.   

Abstract

UNLABELLED: Positron emission tomography (PET) allows non-invasive detection and mapping of tumor hypoxia. However, slow tracer kinetics and low resolution, results in limited tumor-to-normal tissue contrast and the risk of missing areas where hypoxic cells are intermixed with necrosis. The shape of tumor time activity curves (TACs), as deduced from dynamic scans, may allow further separation of tumors/tumor sub-volumes that are inseparable based on static scans. This study was designed to define the added value of dynamic scans.
MATERIAL AND METHODS: Three squamous cell carcinoma tumor models were grown in mice. Mice were injected with the (18)F-labeled PET hypoxia-tracer fluoroazomycin arabinoside (FAZA) and the immunologically-detectable hypoxia-marker pimonidazole, and PET scanned dynamically for three to six hours. Subsequently, microregional tracer retention (autoradiography) and the distribution of pimonidazole-retaining cells (immunohistology) and necrosis were analyzed in tumor tissue sections. Dynamic PET data were analysed based on a two-compartment model with irreversible tracer binding generating estimates of the putative hypoxia surrogate markers k(3) (tracer trapping rate constant) and K(i) (influx rate constant from plasma into irreversible bound tracer). RESULTS/DISCUSSION: High tumor-to-reference tissue ratios and a strong linear correlation (R∼0.7 to 0.95) between density of hypoxic cells and FAZA concentration was observed three hours after tracer administration, suggesting that late time PET images provides an accurate measure of hypoxia against which kinetic model estimates can be validated. Tumor TACs varied widely (ranging from distinctly wash-out to accumulative type) among tumor types although pimonidazole-stainings revealed extensive hypoxia in all models. Kinetic analysis of tumor sub-volumes showed that k(3) correlated poorly with late time FAZA retention regionally in two of the three tumor models. The influx rate constant K(i) displayed far less variability and correlated strongly with late time FAZA retention (hypoxia) in two of three tumor models, whereas a non-consistent relationship was observed in the last tumor model. Our study demonstrates the potential usefulness of dynamic PET, but also that a simple two-compartment model may be inappropriate in some tumor models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20831479     DOI: 10.3109/0284186X.2010.503970

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  15 in total

Review 1.  Kinetic modeling in PET imaging of hypoxia.

Authors:  Fan Li; Jesper T Joergensen; Anders E Hansen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 2.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

3.  Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.

Authors:  Eline E Verwer; Floris H P van Velden; Idris Bahce; Maqsood Yaqub; Robert C Schuit; Albert D Windhorst; Pieter Raijmakers; Adriaan A Lammertsma; Egbert F Smit; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-06       Impact factor: 9.236

Review 4.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.

Authors:  M Busk; L S Mortensen; M Nordsmark; J Overgaard; S Jakobsen; K V Hansen; J Theil; J F Kallehauge; F P D'Andrea; T Steiniche; M R Horsman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-18       Impact factor: 9.236

6.  Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology.

Authors:  Pamela Mena-Romano; Caixia Cheng; Christin Glowa; Peter Peschke; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss; Christian P Karger
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

7.  In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors.

Authors:  Morten Busk; Kasper Toustrup; Brita S Sørensen; Jan Alsner; Michael R Horsman; Steen Jakobsen; Jens Overgaard
Journal:  BMC Cancer       Date:  2011-02-09       Impact factor: 4.430

8.  Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).

Authors:  Florian C Maier; Manfred Kneilling; Gerald Reischl; Funda Cay; Daniel Bukala; Andreas Schmid; Martin S Judenhofer; Martin Röcken; Hans-Jürgen Machulla; Bernd J Pichler
Journal:  Radiat Oncol       Date:  2011-11-25       Impact factor: 3.481

9.  Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts.

Authors:  Pernille B Elming; Thomas R Wittenborn; Morten Busk; Brita S Sørensen; Mathilde Borg Houlberg Thomsen; Trine Strandgaard; Lars Dyrskjøt; Steffen Nielsen; Michael R Horsman
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.

Authors:  Milan Grkovski; Jazmin Schwartz; Mithat Gönen; Heiko Schöder; Nancy Y Lee; Sean D Carlin; Pat B Zanzonico; John L Humm; Sadek A Nehmeh
Journal:  J Nucl Med       Date:  2015-11-25       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.